Targeting the endothelin axis in prostate carcinoma

Tumor Biology

Volumn 33, Issue 2, 2012, Pages 421-426

  Pinto, Álvaro ^a   Merino, María ^a   Zamora, Pilar ^a   Redondo, Andrés ^a   Castelo, Beatriz ^a   Espinosa, Enrique ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Atrasentan; Endothelins; Prostate carcinoma; Zibotentan

Indexed keywords

ALKALINE PHOSPHATASE; ATRASENTAN; DOCETAXEL; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ZIBOTENTAN; ZOLEDRONIC ACID; ENDOTHELIN; PYRROLIDINE DERIVATIVE;

ANALGESIA; ANGIOGENESIS; BONE METABOLISM; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CARCINOMA CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; EDEMA; HUMAN; MONOTHERAPY; NOSE CONGESTION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RHINITIS; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; BONE; CARCINOMA; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; GENE EXPRESSION REGULATION; MALE; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PROSTATE TUMOR;

BONE AND BONES; CARCINOMA; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; ENDOTHELINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PYRROLIDINES;

EID: 84860278133     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0299-6     Document Type: Review

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
3. Berthold RD, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX327 study. J Clin Oncol. 2008;26:242-5.
4. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12(20 Suppl):6296s-300s.
5. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2004;2:16.
6. Obara K, Koide M, Ishikawa T, Tanabe Y, Nakayama K. Protein kinase C ä but not PKC epsilon activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery. J Cardiovasc Pharmacol. 2000;36:S120-1.
7. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides. 1993;14:385-99.
8. Nelson JB, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110-6.
9. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signaling by G-protein-coupled receptors. Nature. 1996;379:557-60.
10. Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM, Shen R. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Mol Carcinog. 2009;48(2):141-9.
11. Spinella F, Garrafa E, Di Castro V, Rosano L, Nicotra MR, Caruso A, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 2009;69 (6):2669-76.
12. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer. 2007;14(2):233-44.
13. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12:6213s-6s.
14. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci. 2001;21:999-1006.
15. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med. 2001;2:24-7.
16. Yuyama H, Koakutsu A, Fuiyasu N, et al. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol. 2004;492:177-82.
17. Jarvis MF, Wessale JL, Zhu CZ, et al. ABT-627, an endothelin ET (A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol. 2000;388:29-35.
18. Bagnato A, Spinella F, Rosano L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer. 2005;12:761-72.
19. Felx M, Guyot MC, Isler M, Turcotte RE, Doyon J, Khatib AM, et al. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond). 2006;110(6):645-54.
20. Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol. 2008;40:1443-51.
21. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291(1):59-66.
22. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944-9.
23. Herrmann E, Bogemann M, Bierer S, et al. The endothelin axis in urologic tumor: mechanisms of tumor biology and therapeutic implications. Exp Rev Anticancer Ther. 2006;6:73-81.
24. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663-8.
25. Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor A associated with prostate cancer progression. J Urol. 2001;165:1033-6.
26. Godara G, Cannon GW, Cannon Jr GM, et al. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate. 2005;65:27-34.
27. Montironi R, Mazzucchelli R, Barbisan F, Stramazotti D, Santinelli A, Lopez-Beltran A, et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in highgrade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol. 2007;52:1682-90.
28. Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001;49:267-77.
29. Wang Y, Chen J, Li Q, et al. Identifying novel prostate cancer associated pathways based on integrative microarray data analysis. Comput Biol Chem. 2011;35(3):151-8.
30. Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1 beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine. 1999;11(2):157-62.
31. Wort SJ, Ito M, Chou P, et al. Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kB binding and histone acetylation at specific kB sites. J Biol Chem. 2009;284 (36):24297-305.
32. Patrikidou A, Vlachostergios PJ, Voutsadakis IA, et al. Inverse baseline expression pattern of the NEP/neuropeptides and NFkB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int. 2011;11(1):13.
33. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II placebo-controlled trial. J Clin Oncol. 2003;21(4):679-89.
34. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006;107:530-5.
35. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA. A phase III randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959-66.
36. Nelson JB, Lowe W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113(9):2478-87.
37. Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008;14(19):6270-6.
38. James ND, Caty A, Payne H, Borre M, Zonnenber BA, Beuzeboc P, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo controlled, randomized phase II trial. BJU Int. 2010;106(7):966-73.
39. Nelson JB, Fizazi K, Miller K, Higano CS, Moul JW, Morris T et al. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castrationresistant prostate cancer. J Clin Oncol 2011;29(suppl 7; abstr 117).
40. Grande M, Carlstrom K, Stege R, Pousette A, Faxen M. Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells. Eur Urol. 2002;41(5):568-72.
41. Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001;49(4):267-77.
42. Strijbos MH, Gratama JW, Schmitz PI, et al. Circulating endothelial cells, circulating tumor cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer. 2010;46(11):2027-35.